Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC
A randomized controlled study to compared the clinical effects and safety of immunotherapy with dendritic cells and cytokine-induced killer cells administered with anti-PD-1 antibody in advanced NSCLC.
Lung Cancer|Neoplasms
BIOLOGICAL: Anti-PD-1 plus DC-CIK|BIOLOGICAL: Anti-PD-1 alone
Progression-free survival of the participants, From starting date of anti-PD-1 antibody treatment until date of until the date of first documented disease progression or date of death from any cause, whichever comes first., 12 months
Overall survival of the participants(OS), From starting date of anti-PD-1 antibody treatment until date of death from any cause, 24 months|Assessment of Patient- Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PROCTCAE), To assess and compare the PRO-CTCAE by patients receiving immunotherapy, 24 months|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, 24 months|Molecular Tumor Burden Index, Using mutation detection in ctDNA by liquid biopsy to assess tumor dynamics, 24 months
Cell-free tumor DNA, To investigate the relationship of ctDNA with clincial outcomes, 24 months|Tumor related antigen peptides, To investigate the relationship of tumor related antigen peptides with clincial outcomes, 24 months|T cell metaboic activity, To investigate the relationship of T cell metaboic activity with clincial outcomes, 24 months|Microbial bacteria, To investigate the relationship of microbial bacteria with clincial outcomes, 24 months
A randomized controlled study to compared the clinical effects and safety of immunotherapy with dendritic cells and cytokine-induced killer cells administered with anti-PD-1 antibody in advanced NSCLC.